How to buy Cingulate stock (CING)

Cingulate is a biotechnology business based in the US. Cingulate shares (CING) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $4.86 – an increase of 18.54% over the previous week. Cingulate employs 13 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Cingulate stock

Buy Cingulate stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Cingulate stock price (NASDAQ: CING)

Use our graph to track the performance of CING stocks over time.

Cingulate shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$4.86
52-week range	$1.80 - $152.40
50-day moving average more info button	$4.29
200-day moving average more info button	$7.30
Wall St. target price	$48.33
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-43.22

Is it a good time to buy Cingulate stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Cingulate price performance over time

Historical closes compared with the close of $4.76 from 2024-12-23

1 week (2024-12-18)	16.10%
1 month (2024-11-25)	1.28%
3 months (2024-09-25)	-7.57%
6 months (2024-06-25)	712.29%

1 year (2023-12-22)	128.85%
2 years (2022-12-23)	-97.93%
3 years (2021-12-23)	612
5 years (2019-12-21)	N/A

Cingulate financials

Gross profit TTM	$-8,995,280
Return on assets TTM	-104.33%
Return on equity TTM	-273.82%
Profit margin	0%
Book value	$6.82
Market Capitalization more info button	$13.2 million

TTM: trailing 12 months

Cingulate share dividends

We're not expecting Cingulate to pay a dividend over the next 12 months.

You may also wish to consider:

• Pfizer (PFE.US) (6.64% forward annual dividend yield)
• Johnson-and-Johnson (JNJ.US) (3.43% forward annual dividend yield)
• Eli Lilly and Company (LLY.US) (0.78% forward annual dividend yield)

Have Cingulate's shares ever split?

Cingulate's shares were split on a 1:12 basis on 8 August 2024 . So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cingulate shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Cingulate shares which in turn could have impacted Cingulate's share price.

Cingulate share price volatility

Over the last 12 months, Cingulate's shares have ranged in value from as little as $1.8001 up to $152.4. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cingulate's is -0.907. This would suggest that Cingulate's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Cingulate has bucked the trend.

To put Cingulate's beta into context you can compare it against those of similar companies.

• Pfizer (PFE.US): 0.615
• Johnson-and-Johnson (JNJ.US): 0.518
• Eli Lilly and Company (LLY.US): 0.43

Cingulate overview

Cingulate Inc. , a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas. .

Frequently asked questions

null
What percentage of Cingulate is owned by insiders or institutions?
Currently 3.3% of Cingulate shares are held by insiders and 1.557% by institutions. How many people work for Cingulate?
Latest data suggests 13 work at Cingulate. When does the fiscal year end for Cingulate?
Cingulate's fiscal year ends in December. Where is Cingulate based?
Cingulate's address is: 1901 West 47th Place, Kansas City, KS, United States, 66205 What is Cingulate's ISIN number?
Cingulate's international securities identification number is: US17248W1053